eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | multiple endocrine neoplasia type 1 |
| Comorbidity | C0007113|rectal cancer |
| Sentences | 13 |
| PubMedID- 24818022 | A postauthorization survey to document the therapeutic management of oxaliplatin as a first-line chemotherapy regimen in south africa in patients with metastatic colorectal cancer. |
| PubMedID- 24388340 | Methods: an electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer. |
| PubMedID- 23439317 | Conclusions: this new s-1 and irinotecan combination schedule appeared to be an effective, well-tolerated, and convenient regimen in patients with advanced colorectal cancer as compared with conventional regimens such as folfiri and iris. |
| PubMedID- 20221830 | Phase ii study of folfiri regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin. |
| PubMedID- 19729318 | Conclusion: folfoxiri does not seem to offer substantial benefit compared to folfiri regimen in elderly patients with metastatic colorectal cancer. |
| PubMedID- 22199346 | Aim: this is a multicenter phase ii study to assess the efficacy and toxicity of the 5-fu, leucovorin, and oxaliplatin (flox) (swift 3) regimen in japanese patients with advanced colorectal cancer (crc). |
| PubMedID- 23755925 | Discordance of kras mutational status in a single colonic resection specimen in a patient with colorectal cancer: a case report and review of the literature. |
| PubMedID- 22555197 | Conclusions: our results indicate that iris is a promising first-line regimen in patients with metastatic colorectal cancer. |
| PubMedID- 24762224 | Xelox-bevacizumab for 6 cycles followed by bevacizumab-erlotinib maintenance therapy has been shown to be a highly active and well-tolerated first-line regimen in patients with metastatic colorectal cancer. |
| PubMedID- 26475356 | Background: the aim of this multicenter, open-label, randomized phase ii trial was to evaluate the efficacy of a dose-dense capecitabine and oxaliplatin (xelox) regimen in patients with metastatic colorectal cancer (mcrc) for whom reintroduction of oxaliplatin had been planned as a third- or later-line regimen. |
| PubMedID- 25947298 | Until then, endoscopic ink tattooing should be used if needed to mark the site of the tumour before surgical resection (e.g., small lesions, laparoscopic surgery), but not to increase the number of lymph nodes retrieved from specimen in patients with colorectal cancer. |
| PubMedID- 24692743 | However, the efficacy and toxicity of this regimen in japanese patients with metastatic colorectal cancer remain unknown. |
| PubMedID- 21449681 | Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer. |
Page: 1